Instagram updates could help pharma tap new audiences--and maybe get creative, too
20 February 2016
Pharma brand managers celebrated earlier this year when Twitter proposed a 10,000-character limit. But new changes to Instagram could give pharma marketers even more of a boost, one industry marketing expert said, as companies harness the platform's updated features to tap in to new audiences.
China renews consolidation drive for drug manufacture, wants TCM push
20 February 2016
China's leadership renewed a drive to winnow out bad quality drug manufacturers and improve safety as part of a State Council meeting that updated on an ambitious program of healthcare reforms calling for access to newer therapies and greater use of traditional Chinese medicines (TCM).
Groundbreaking STI test can detect chlamydia in 30 minutes
19 February 2016
The Atlas io system was created by the University of Bath's spin-off biotech company Atlas Genetics in 2005. It has now won approval from the EU to be sold. The development means that patients can be tested and treated for the disease within a single clinic visit.
With pricing power waning, time for Big Pharma to become a lean, mean, well-oiled machine
19 February 2016
Waiting for the halcyon days when drugmakers could price drugs without pushback to return? Don't, GlaxoSmithKline ($GSK) U.S. pharma president Jack Bailey says. You'd be better off cutting costs instead.
Got plenty of cash? Market carnage sets up a Darwinian showdown in biotech
19 February 2016
These days, when you talk to a biotech CEO, it's not unusual for the conversation to turn to just how much cash they have in the bank, and just how far out that runway extends in covering costs.
China push to bring biotech talent home is paying off
19 February 2016
China's output of academic papers in the biotech realm has grown in volume and quality over nearly a decade as efforts to lure Chinese talent in the biotech industry back home pays off.
The Staying Power of Emerging Markets
18 February 2016
Whatever used to be wrong with the world of big Pharma could be fixed with a single tag phrase: emerging country markets. Most of the majors have invested heavily in this geographic segment, and the biggest of the big—companies like Novartis—now rely on it for more than a quarter of their global sales. Like all good things, however, there are shadows amidst the sunlight, and the task of turning volume sales into sustainable profits is getting harder. Economic growth in these markets is fading as commodity prices ditch in tandem with capital flight and a rising public and private debt burden. Local governance challenges are adding to the risk of building the reputation essential to securing commercial rewards.
Europe Implements Measures to Prevent Falsified Medicines
18 February 2016
On Feb. 9, 2016, the European Medicines Agency (EMA) and the European Commission (EC) announced a plan to implement packaging safety features as part of the Falsified Medicines Directive (Directive 2011/62/EU) (FMD), adopted in July 2011. The implementation plan for centrally authorized medicines was created as a guide for applicants and marketing-authorization holders so they can meet the FMD requirements. These safety measures are part of Europe’s fight against falsified medicines. EMA defines falsified medicines as “fake medicines that pass themselves off as real, authorized medicines.”
Gold nanoparticle clusters and bursts of infrared light eliminate postsurgery tumor cells
17 February 2016
After tumor removal surgery, any part of the tumor that is left could potentially once again be harmful and spread. Now, using clusters of gold nanoparticles and short bursts of infrared light, researchers have homed in on those remaining cells to eradicate traces of the tumor with precision.
Fine Tuning the Focus on Biopharma Analytical Studies
17 February 2016
Although just a few decades old, the biopharmaceutical industry has evolved significantly since its inception. Many candidate biologics today—antibodies and antibody fragments, highly potent antibody-drug conjugates (ADCs), virus-like particles, cell- and gene-based therapies, etc.—are different from the first simple, recombinant proteins. Manufacturers have been continuously challenged to develop analytical methods for timely and accurate determination of the chemical, physical, and therapeutic properties of these different actives, as well as potential contaminants throughout the production process, from raw material selection to process analysis, formulation development, and release testing.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024